BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18446624)

  • 1. Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource.
    Loughrey M; Provan PJ; Byth K; ; Balleine RL
    Pathology; 2008 Jun; 40(4):352-8. PubMed ID: 18446624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
    Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
    Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
    Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
    Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry.
    Mocci E; Milne RL; Méndez-Villamil EY; Hopper JL; John EM; Andrulis IL; Chung WK; Daly M; Buys SS; Malats N; Goldgar DE
    Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):803-11. PubMed ID: 23456555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
    Balleine RL; Provan PJ; Pupo GM; Pathmanathan N; Cummings M; Farshid G; Salisbury EL; Bilous AM; Byth K; ; Mann GJ
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1082-94. PubMed ID: 20815029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological features of breast cancer in carriers of ATM gene variants.
    Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
    Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
    Didraga MA; van Beers EH; Joosse SA; Brandwijk KI; Oldenburg RA; Wessels LF; Hogervorst FB; Ligtenberg MJ; Hoogerbrugge N; Verhoef S; Devilee P; Nederlof PM
    Breast Cancer Res Treat; 2011 Nov; 130(2):425-36. PubMed ID: 21286804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-BRCA familial breast cancer: review of reported pathology and molecular findings.
    Keeney MG; Couch FJ; Visscher DW; Lindor NM
    Pathology; 2017 Jun; 49(4):363-370. PubMed ID: 28450088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "portrait" of hereditary breast cancer.
    Lacroix M; Leclercq G
    Breast Cancer Res Treat; 2005 Feb; 89(3):297-304. PubMed ID: 15754129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families.
    Jernström H; Sellberg G; Borg A; Olsson H
    Eur J Cancer Prev; 2006 Jun; 15(3):233-41. PubMed ID: 16679866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
    Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
    Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
    PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
    Hedenfalk I; Ringner M; Ben-Dor A; Yakhini Z; Chen Y; Chebil G; Ach R; Loman N; Olsson H; Meltzer P; Borg A; Trent J
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2532-7. PubMed ID: 12610208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
    Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
    PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.